Should Valve Leaflet Thickening Be Considered a Characteristic Lesion of Infective Endocarditis?
Clinical Infectious Diseases · 30.08.2026
DOI: 10.1093/cid/ciag524 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 30.08.2026. Verfasst von Georgios Tzimas und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swiss National Science Foundation, Swiss Heart Foundation, Vaudois Foundation.
Abstract (Originalsprache)
Background
Valve leaflet thickening was recently incorporated into the 2023 version of the Duke criteria by the European Society of Cardiology (ESC) as a potential imaging marker of infective endocarditis (IE). The study aimed to assess the impact of valve leaflet thickening on the diagnosis of IE among patients investigated for suspected IE.
Methods
This retrospective study included adults with suspected IE at Lausanne University Hospital (2014–2025). IE was diagnosed by the 2023 Duke-ISCVID based on the clinical, pathological, and rejection criteria. Reclassification of IE status was assessed according to the 2023 Duke-ESC clinical criteria with and without inclusion of leaflet thickening.
Results
Among 3747 episodes of suspected IE, valve leaflet thickening was identified in 288 (8%). IE was diagnosed in 193/288 (67%) episodes. Among the 193 IE episodes, 62 (32%) showed no additional intracardiac lesion typically associated with IE. When leaflet thickening was excluded from imaging criteria, 144 episodes (50%) still fulfilled a major imaging criterion according to the 2023 Duke-ESC clinical criteria. Incorporation of leaflet thickening into the 2023 Duke-ESC clinical criteria increased sensitivity from 59% (95% confidence interval [CI]: 52%–66%) to 79% (95% CI: 73%–85%), while specificity decreased from 98% (95% CI: 93%–100%) to 46% (95% CI: 36%–57%).
Conclusions
Valve leaflet thickening is a frequent but nonspecific imaging finding that substantially reduces diagnostic specificity when incorporated into the 2023 Duke-ESC clinical criteria. Its use as a major imaging criterion risks overdiagnosis and overtreatment, underscoring the need for cautious interpretation within a multidisciplinary diagnostic framework.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
- Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
- Department of Cardiac Surgery, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
- Infectious Diseases Service, Hospital of Valais and Institut Central des Hôpitaux, Sion, Switzerland.
ORCID-Profile: Georgios Tzimas, Pierre Monney, Panagiotis Antiochos, Lars Niclauss, Matthias Kirsch, Matthaios Papadimitriou-Olivgeris
Förderung
- Swiss National Science Foundation
- Swiss Heart Foundation
- Vaudois Foundation
Zitieren
APA
Tzimas, G., Monney, P., Ianculescu, N., Antiochos, P., Guery, B., Niclauss, L., Kirsch, M., & Papadimitriou-Olivgeris, M. (2026). Should Valve Leaflet Thickening Be Considered a Characteristic Lesion of Infective Endocarditis?. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciag524
Vancouver
Tzimas G, Monney P, Ianculescu N, Antiochos P, Guery B, Niclauss L, et al. Should Valve Leaflet Thickening Be Considered a Characteristic Lesion of Infective Endocarditis?. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciag524
BibTeX
@article{Tzimas2026,
author = {Tzimas, Georgios and Monney, Pierre and Ianculescu, Nicoleta and Antiochos, Panagiotis and Guery, Benoit and Niclauss, Lars and Kirsch, Matthias and Papadimitriou-Olivgeris, Matthaios},
title = {Should Valve Leaflet Thickening Be Considered a Characteristic Lesion of Infective Endocarditis?},
journal = {Clinical Infectious Diseases},
year = {2026},
doi = {10.1093/cid/ciag524}
}
EUVIMED